A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

Neuro-Oncology

Volumn 12, Issue 2, 2010, Pages 181-189

  Kreisl, Teri N ^a   Kotliarova, Svetlana ^a   Butman, John A ^a   Albert, Paul S ^b   Kim, Lyndon ^a   Musib, Luna ^c   Thornton, Donald ^c   Fine, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Biomarker; Glioblastoma; Malignant glioma; Targeted therapy

Indexed keywords

CARBAMAZEPINE; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3; LY 326020; LY 485912; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN HEMORRHAGE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EMBOLISM; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; GLIOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; INDOLES; KAPLAN-MEIERS ESTIMATE; NEOPLASM RECURRENCE, LOCAL;

EID: 75849133697     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop042     Document Type: Article

References (20)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J ClinOncol. 2007;25(12):1539-1544.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
4. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol. 1997;93(2):109-117.
5. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59(4):520-529.
6. Vredenburgh JJ, Desjardins A, Herndon JE, II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729.
7. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53(2):133-140.
8. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol. 2002;49(1):69-77.
9. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(13):1741-1746.
10. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462-7469.
11. Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kB, and glucose regulation. Cancer Res. 2008;68(16): 6643-6651.
12. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61(2): 153-161.
13. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578.
14. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47(3): 329-335.
15. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
17. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24(25): 4092-4099.
18. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost. 1993;70(3): 393-396.
19. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 2008;10(2):162-170.
20. Fine HA, Puduvalli VK, Chamberlain MC, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study. ASCO Meeting Abstracts; May 20, 2008; 26(suppl 15):2005.